Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders

In recent years, multiparameter flow cytometry (MFC) immunophenotyping has become mandatory in the clinical management of hematological malignancies, both for diagnostic and monitoring purposes. Multiple myeloma (MM) and other clonal plasma cell‐related (PC) disorders should be no exception to this...

Full description

Saved in:
Bibliographic Details
Published in:Cytometry. Part B, Clinical cytometry Clinical cytometry, 2010-07, Vol.78B (4), p.239-252
Main Authors: Paiva, Bruno, Almeida, Julia, Pérez‐Andrés, Martin, Mateo, Gema, López, Antonio, Rasillo, Ana, Vídriales, María‐Belén, López‐Berges, María‐Consuelo, Miguel, Jesús F. San, Orfao, Alberto
Format: Article
Language:English
Subjects:
Cell Movement
clonal plasma cell disorders
Clone Cells
Differential diagnosis
Flow cytometry
Flow Cytometry - methods
Humans
immunophenotyping
Immunophenotyping - methods
Malignancy
minimal residual disease
multiparameter flow cytometry
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - immunology
Plasma Cells - immunology
Plasma Cells - pathology
Risk groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, multiparameter flow cytometry (MFC) immunophenotyping has become mandatory in the clinical management of hematological malignancies, both for diagnostic and monitoring purposes. Multiple myeloma (MM) and other clonal plasma cell‐related (PC) disorders should be no exception to this paradigm, but incorporation of immunophenotypic studies in the management of patients with PC disorders is still far from being routinely established in many diagnostic flow cytometry laboratories. For clonal PC disorders, MFC is of clear and established clinical relevance in: (1) the differential diagnosis between MM and other PC‐related disorders; (2) the identification of high‐risk MGUS and smoldering MM; (3) minimal residual disease investigation after therapy; additionally it may also be useful for (4) the definition of prognosis‐associated antigenic profiles; and (5) the identification of new therapeutic targets. In this article, we review the clinical value of MFC in the study of PC disorders, with specific emphasis in those areas where consensus exists on the need to incorporate MFC into routine evaluation of MM and other clonal PC‐related disorders. © 2010 Clinical Cytometry Society
ISSN:1552-4949
1552-4957
1552-4957
DOI:10.1002/cyto.b.20512